This trial is testing a combination of two immunotherapy drugs, TAK-676 and pembrolizumab, to see if they can improve outcomes for people with non-small cell lung cancer, triple-negative breast cancer, and squamous cell carcinoma of the head and neck.
- Squamous Cell Carcinoma of the Head and Neck
- Non-Small Cell Lung Cancer
- Triple Negative Breast Cancer
4 Primary · 20 Secondary · Reporting Duration: Up to 30 months
1 Treatment Group
Combination Dose Escalation Phase: Radiation + Pembrolizumab + TAK-676
1 of 1
65 Total Participants · 1 Treatment Group
Primary Treatment: TAK-676 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 3 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there still openings for potential study participants?
"Affirmative. Clinicaltrials.gov's details demonstrate that this study, which was initially posted on September 9th 2021, is still open to new participants. 65 individuals are anticipated at seven different clinical sites." - Anonymous Online Contributor
Are there any previous experiments conducted involving TAK-676?
"Presently, there are 961 experiments ongoing that utilize TAK-676 with 122 Phase 3 trials. Houston, TX hosts a number of these tests; however, the total count for locations running TAK-676 studies is 35731." - Anonymous Online Contributor
What potential risks have been observed with TAK-676 administration?
"There is scarce data confirming the efficacy and safety of TAK-676, thus it was assigned a score of 1." - Anonymous Online Contributor
Are there any Canadian healthcare facilities participating in this research?
"Patients can access this clinical trial at the Providence Portland Medical Center (Portland, Oregon), Cedars Sinai Medical Centre (Pittsburgh, Pennsylvania) and Laura And Isaac Perlmutter Cancer Center (West Hollywood, California). There are 7 other accessible sites." - Anonymous Online Contributor
What is the ultimate goal of this clinical investigation?
"Takeda Pharmaceuticals, the trial sponsor, has outlined a range of primary and secondary outcomes. The primary outcome is Dose-limiting Toxicities (DLT), which will be monitored over a 30 month period from initial drug administration. Additionally, Nonirradiated Overall Response Rate (ORRnonirradiated), Irradiated Overall Response Rate (ORRirradiated) and Standard Overall Response Rate (ORR) are being assessed using RECIST V1.1 criteria as predetermined by the investigator." - Anonymous Online Contributor
What pathologies is TAK-676 typically employed to address?
"TAK-676 can be employed to treat malignant neoplasms, inoperable melanoma, and cases of high microsatellite instability." - Anonymous Online Contributor
Approximately how many participants have been included in this research endeavor?
"Takeda, the sponsor of this trial, requires 65 patients to meet their inclusion criteria in order for it to begin. The study will be taking place at Providence Portland Medical Center (Oregon) and Cedars Sinai Medical Centre (Pennsylvania)." - Anonymous Online Contributor